-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 22, the official website of NMPA showed that Shandong New Times Pharmaceutical was approved to market with imitation 4 types of ivabradine hydrochloride tablets, making it the third domestic manufacturer
.
According to data from Menet.
com, the sales of terminal ivabradine in China's public medical institutions rose by more than 120% in the first half of 2021
.
Since the beginning of this year, Shandong New Times Pharmaceuticals has been approved for the listing of 8 varieties
.
.
According to data from Menet.
com, the sales of terminal ivabradine in China's public medical institutions rose by more than 120% in the first half of 2021
.
Since the beginning of this year, Shandong New Times Pharmaceuticals has been approved for the listing of 8 varieties
.
Ivabradine is an If inhibitor, which reduces heart rate by selectively and specifically inhibiting cardiac pacing If current
.
Servier's ivabradine hydrochloride tablets were first approved for marketing in France in October 2005, approved for marketing in the United States in April 2015, and approved for marketing in China in May of the same year
.
.
Servier's ivabradine hydrochloride tablets were first approved for marketing in France in October 2005, approved for marketing in the United States in April 2015, and approved for marketing in China in May of the same year
.
According to data from Menet.
com, the domestic market of ivabradine has continued to rise in recent years.
In 2020, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 100 million yuan.
, An increase of 118.
59% year-on-year; sales in the first half of 2021 exceeded 100 million yuan, an increase of 123.
63% year-on-year
.
com, the domestic market of ivabradine has continued to rise in recent years.
In 2020, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 100 million yuan.
, An increase of 118.
59% year-on-year; sales in the first half of 2021 exceeded 100 million yuan, an increase of 123.
63% year-on-year
.
Sales of terminal ivabradine in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
On May 19, 2021, Ivabradine Hydrochloride Tablets of Beijing Baiao Pharmaceutical was approved for marketing, becoming the first imitation in China
.
On October 26, Chongqing Decheng Yongdao Pharmaceutical 's ivabradine hydrochloride tablets were approved for the market, making it the second domestic manufacturer
.
On December 22, Shandong New Times Pharmaceutical's Ivabradine Hydrochloride Tablets were approved for the market, making it the third domestic producer
.
.
On October 26, Chongqing Decheng Yongdao Pharmaceutical 's ivabradine hydrochloride tablets were approved for the market, making it the second domestic manufacturer
.
On December 22, Shandong New Times Pharmaceutical's Ivabradine Hydrochloride Tablets were approved for the market, making it the third domestic producer
.
Products approved for listing by New Era Pharmaceutical from 2021 to present
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since the beginning of this year, Shandong New Times Pharmaceuticals has been approved for the listing of 8 varieties
.
Except for the long-acting Shengbaiyao PEGylated recombinant human granulocyte stimulating factor injection, the remaining 7 varieties have been approved for production under the new registration classification, which are deemed to have passed the consistency evaluation
.
Among them, axitinib tablets are the first domestic imitation + first review, epirubicin hydrochloride injection is the first domestic review, and ivabradine hydrochloride tablets are the third domestic
.
.
Except for the long-acting Shengbaiyao PEGylated recombinant human granulocyte stimulating factor injection, the remaining 7 varieties have been approved for production under the new registration classification, which are deemed to have passed the consistency evaluation
.
Among them, axitinib tablets are the first domestic imitation + first review, epirubicin hydrochloride injection is the first domestic review, and ivabradine hydrochloride tablets are the third domestic
.
Data source: Mi Neiwang database, NMPA
On December 22, the official website of NMPA showed that Shandong New Times Pharmaceutical was approved to market with imitation 4 types of ivabradine hydrochloride tablets, making it the third domestic manufacturer
.
According to data from Menet.
com, the sales of terminal ivabradine in China's public medical institutions rose by more than 120% in the first half of 2021
.
Since the beginning of this year, Shandong New Times Pharmaceuticals has been approved for the listing of 8 varieties
.
.
According to data from Menet.
com, the sales of terminal ivabradine in China's public medical institutions rose by more than 120% in the first half of 2021
.
Since the beginning of this year, Shandong New Times Pharmaceuticals has been approved for the listing of 8 varieties
.
Ivabradine is an If inhibitor, which reduces heart rate by selectively and specifically inhibiting cardiac pacing If current
.
Servier's ivabradine hydrochloride tablets were first approved for marketing in France in October 2005, approved for marketing in the United States in April 2015, and approved for marketing in China in May of the same year
.
.
Servier's ivabradine hydrochloride tablets were first approved for marketing in France in October 2005, approved for marketing in the United States in April 2015, and approved for marketing in China in May of the same year
.
According to data from Menet.
com, the domestic market of ivabradine has continued to rise in recent years.
In 2020, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 100 million yuan.
, An increase of 118.
59% year-on-year; sales in the first half of 2021 exceeded 100 million yuan, an increase of 123.
63% year-on-year
.
com, the domestic market of ivabradine has continued to rise in recent years.
In 2020, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 100 million yuan.
, An increase of 118.
59% year-on-year; sales in the first half of 2021 exceeded 100 million yuan, an increase of 123.
63% year-on-year
.
Sales of terminal ivabradine in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
On May 19, 2021, Ivabradine Hydrochloride Tablets of Beijing Baiao Pharmaceutical was approved for marketing, becoming the first imitation in China
.
On October 26, Chongqing Decheng Yongdao Pharmaceutical 's ivabradine hydrochloride tablets were approved for the market, making it the second domestic manufacturer
.
On December 22, Shandong New Times Pharmaceutical's Ivabradine Hydrochloride Tablets were approved for the market, making it the third domestic producer
.
.
On October 26, Chongqing Decheng Yongdao Pharmaceutical 's ivabradine hydrochloride tablets were approved for the market, making it the second domestic manufacturer
.
On December 22, Shandong New Times Pharmaceutical's Ivabradine Hydrochloride Tablets were approved for the market, making it the third domestic producer
.
Products approved for listing by New Era Pharmaceutical from 2021 to present
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since the beginning of this year, Shandong New Times Pharmaceuticals has been approved for the listing of 8 varieties
.
Except for the long-acting Shengbaiyao PEGylated recombinant human granulocyte stimulating factor injection, the remaining 7 varieties have been approved for production under the new registration classification, which are deemed to have passed the consistency evaluation
.
Among them, axitinib tablets are the first domestic imitation + first review, epirubicin hydrochloride injection is the first domestic review, and ivabradine hydrochloride tablets are the third domestic
.
.
Except for the long-acting Shengbaiyao PEGylated recombinant human granulocyte stimulating factor injection, the remaining 7 varieties have been approved for production under the new registration classification, which are deemed to have passed the consistency evaluation
.
Among them, axitinib tablets are the first domestic imitation + first review, epirubicin hydrochloride injection is the first domestic review, and ivabradine hydrochloride tablets are the third domestic
.
Data source: Mi Neiwang database, NMPA
On December 22, the official website of NMPA showed that Shandong New Times Pharmaceutical was approved to market with imitation 4 types of ivabradine hydrochloride tablets, making it the third domestic manufacturer
.
According to data from Menet.
com, the sales of terminal ivabradine in China's public medical institutions rose by more than 120% in the first half of 2021
.
Since the beginning of this year, Shandong New Times Pharmaceuticals has been approved for the listing of 8 varieties
.
.
According to data from Menet.
com, the sales of terminal ivabradine in China's public medical institutions rose by more than 120% in the first half of 2021
.
Since the beginning of this year, Shandong New Times Pharmaceuticals has been approved for the listing of 8 varieties
.
Ivabradine is an If inhibitor, which reduces heart rate by selectively and specifically inhibiting cardiac pacing If current
.
Servier's ivabradine hydrochloride tablets were first approved for marketing in France in October 2005, approved for marketing in the United States in April 2015, and approved for marketing in China in May of the same year
.
Heart, heart, heart.
Servier's ivabradine hydrochloride tablets were first approved for marketing in France in October 2005, approved for marketing in the United States in April 2015, and approved for marketing in China in May of the same year
.
According to data from Menet.
com, the domestic market of ivabradine has continued to rise in recent years.
In 2020, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 100 million yuan.
, An increase of 118.
59% year-on-year; sales in the first half of 2021 exceeded 100 million yuan, an increase of 123.
63% year-on-year
.
Hospital hospital hospitalcom, the domestic market of ivabradine has continued to rise in recent years.
In 2020, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 100 million yuan.
, An increase of 118.
59% year-on-year; sales in the first half of 2021 exceeded 100 million yuan, an increase of 123.
63% year-on-year
.
Sales of terminal ivabradine in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
On May 19, 2021, Ivabradine Hydrochloride Tablets of Beijing Baiao Pharmaceutical was approved for marketing, becoming the first imitation in China
.
On October 26, Chongqing Decheng Yongdao Pharmaceutical 's ivabradine hydrochloride tablets were approved for the market, making it the second domestic manufacturer
.
On December 22, Shandong New Times Pharmaceutical's Ivabradine Hydrochloride Tablets were approved for the market, making it the third domestic producer
.
Medicine Medicine Medicine.
On October 26, Chongqing Decheng Yongdao Pharmaceutical 's ivabradine hydrochloride tablets were approved for the market, making it the second domestic manufacturer
.
On December 22, Shandong New Times Pharmaceutical's Ivabradine Hydrochloride Tablets were approved for the market, making it the third domestic producer
.
Products approved for listing by New Era Pharmaceutical from 2021 to present
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since the beginning of this year, Shandong New Times Pharmaceuticals has been approved for the listing of 8 varieties
.
Except for the long-acting Shengbaiyao PEGylated recombinant human granulocyte stimulating factor injection, the remaining 7 varieties have been approved for production under the new registration classification, which are deemed to have passed the consistency evaluation
.
Among them, axitinib tablets are the first domestic imitation + first review, epirubicin hydrochloride injection is the first domestic review, and ivabradine hydrochloride tablets are the third domestic
.
.
Except for the long-acting Shengbaiyao PEGylated recombinant human granulocyte stimulating factor injection, the remaining 7 varieties have been approved for production under the new registration classification, which are deemed to have passed the consistency evaluation
.
Among them, axitinib tablets are the first domestic imitation + first review, epirubicin hydrochloride injection is the first domestic review, and ivabradine hydrochloride tablets are the third domestic
.
Data source: Mi Neiwang database, NMPA
